Cyclacel Pharma (CYCC) Tops Q4 EPS by 6c

Cyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($0.20), $0.06 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $299 thousand, versus $247 thousand reported last year.

Cyclacel reported Q413 loss of $0.21 per share.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
• American Express down 2% in premarket trade after Q2 revenue miss offsets EPS beat
• NextEra Energy (NEE) Tops Q2 EPS by 6c